MedTrace Logo

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

NCT02572323 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2026-03-12

Study results available
· View outcomes & findings →

Summary

The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.

Conditions

Interventions

DRUG

Tesamorelin

Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV

Sponsors & Collaborators

Principal Investigators

  • Ronald J Ellis, MD, PhD · University of California, San Diego

  • Fred Sattler, MD · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2023-10-15
Completion
2023-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02572323 on ClinicalTrials.gov